In January, the U.S. Food and Drug Administration (FDA) issued its first guidance on the use of artificial intelligence (AI)[1] models in drug development and in regulatory submissions titled, ...
The Medicare Innovation Center has proposed two drug pricing models that would lower the cost of certain drugs to reflect international prices, which are often significantly lower than what U.S.
Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to ...
For decades, the pharmaceutical industry has discussed moving away from in vivo models in preclinical research. Now, it’s more than a conversation. The FDA’s roadmap for reducing animal testing, ...
Carlin is a vice president at Pathway Policy Group and a veterinarian. Paragas is the CEO and founder of DVLP Medicines and a virologist. The Food and Drug Administration’s recent decision to phase ...
The GENEROUS Model aims to reduce Medicaid drug costs by aligning prices with international standards, launching in 2026. It builds on existing programs like the Medicaid Drug Rebate Program and the ...
A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...
Forbes contributors publish independent expert analyses and insights. Diane Omdahl is a Medicare expert who keeps her readers in the know. On December 23, the Centers for Medicare and Medicaid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results